Allergic reaction to abciximab with atypical manifestations
Abciximab (ReoPro, Eli Lilly and Company, Indianapolis, Indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions. It is a chimeric monoclonal antibody fragment that binds to the glycoprotein IIb/IIIa receptor with a potential...
| Publié dans: | Journal of the Saudi Heart Association. - 1999. - 23(2011), 2 vom: 20. Apr., Seite 97-9 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2011
|
| Accès à la collection: | Journal of the Saudi Heart Association |
| Sujets: | Journal Article Abciximab Allergic reaction Coronary intervention Glycoprotein IIb/IIIa inhibitor |
| Accès en ligne |
Volltext |